If a vaccine program were implemented today and the vaccine was 100% efficacious and utilized by 100% of the target population, the annualized present value of the cost per QALY gained is $11,000. Using committee assumptions of less-than-ideal utilization and including time and monetary costs until a vaccine program is implemented, the annualized present value of the cost per QALY gained is $16,000.
Anthony BF. Group B Streptococcal Infections. In: Textbook of Pediatric Infectious Diseases. RD Feigin and JD Cherry eds. Philadelphia, PA: WB Saunder Company, 1992, pp. 1305–1316.
Blumberg HM, Stephens DS, Modansky M, et al. Invasive Group B Streptococcal Disease: The Emergence of Serotype V. Journal of Infectious Diseases 1996; 173:365–73.
CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report 1996; 45:1–24.
CDC. Prevention of perinatal group B Streptococcal disease: a public health perspective. Morbidity and Mortality Weekly Report 1996; 45:1–24.
Edwards MS, Baker CJ. Streptococcus Agalactiae (Group B Streptococcus). In: Principles and Practice of Infectious Diseases. GL Mandell, JE Bennett, Dolin R eds. New York, NY: Churchill Livingstone, 1995, pp. 1835–1845.
Farley MM. A Population-Based Assessment of Invasive Disease Due to Group B Streptococcus in Nonpregnant Adults. The New England Journal of Medicine 1993; 328:1807–1811.
Farley MM. Group B Streptococcal Infection in Older Patients. Drugs & Aging 1995; 6:293–300.
Jackson LA, Hilsdon R, Farley MM, et al. Risk Factors for Group B Streptococcal Disease in Adults. Annals of Internal Medicine 1995; 123:415–420.
U.S. Bureau of the Census. Statistical Abstract of the U.S.: 1995 (115th edition). Washington, DC, 1995.
Ventura SJ, Martin JA, Mathews TJ, et al. Advance Report of Final Natality Statistics, 1994. Monthly Vital Statistics Report 1996; 44.